Supplemental Figure 1

Nov 06, 2014

10 likes | 112 Views

Supplemental Figure 1. A. B. Supplemental Figure 1. (A) Dose response curves from MTT assays at 6 days of treatment with indicated concentrations of ICG-001. (B) IC50 values for PDAC cell lines after treatment with ICG-001.

Share Presentation

Embed Code

Link

concentrations
ic50 values
mtt assays
icg 001
supplemental figure 1
dose response curves

amos-noel

Download Presentation

Supplemental Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 1 A B Supplemental Figure 1. (A) Dose response curves from MTT assays at 6 days of treatment with indicated concentrations of ICG-001. (B) IC50 values for PDAC cell lines after treatment with ICG-001.

Supplemental Figure 1

Supplemental Figure 1. Fig. S1 qRT -PCR analysis of the genes flanking the sbp2’ / sbp2’’ knockouts. All values are given relative to the abundance of transcript observed in P1/7. Data presents the mean from 3 biological replicates. .

100 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. d-ROM (Carr U). P = 0.0512. recurrence-free period (day). Correlation between d-ROM levels and recurrence-free period in 36 multicentric occurrence cases using linear regression analysis.

78 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1.

69 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. A. Mock. MOI-100. MOI-10. 0.5%. 79.7%. 21.8%. CD3 PerCP. NY-ESO-1 Tetramer PE. B. C. Supplemental Figure 2. A. Thymus. L Humerus. R Humerus. Muscle. L Femur. R Femur. C. B. P < 0.0001. Supplemental Figure 3. A. B.

154 views • 3 slides

Supplemental Figure 1

Supplemental Figure 1. Isolation of glomeruli in control mice.

99 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. A. P-VEGFR2. Tubulin. PlGF-1 250 ng/mL - + + + + Time (min) - 5 10 15 30. B. P-VEGFR2. Tubulin. C.

93 views • 3 slides

Supplemental Figure 1

A. B. C. D. E. F. Supplemental Figure 1. Supplemental Figure S1. Incidence of CD4+ IFN γ (A) , IL-2 (C) and TNFa (E) responders and magnitude of total IFN γ + (B), IL-2+ (D) and TNFa+ (F) CD4+ T-cell responses in different patient groups

150 views • 6 slides

Supplemental Figure 1

Supplemental Figure 1. SPERM A -. Sp_D62[A-]. Sp_D62[A+]. SPERM A +. Sp_D62[Tt]. SPERM TOTAL. Sp_D64[Tt]. Sp_D66[Tt]. Sp_P1[Tt]. Sp_D62[SP]. SPERM SPIA. Sp_D64[SP]. Sp_D66[SP]. Sp_P2[SP]. Te_PCl[SP]. TESTES SPIA. Te_PAm[A+]. TESTES Poly (A + ). Te_PCl[A+]. PRM2.

179 views • 6 slides

Supplemental Figure 1

Supplemental Figure 1. Patient 2. Supplemental Figure 2. Patient:. 1. 2. 3. No cDNA. No cDNA. No cDNA. - Ac. - Ac. - Ac. - Ac. - Ac. - Ac. IgG. IgG. IgG. IgG. IgG. IgG. IgA. IgA. IgA. IgA. IgA. IgA. Patient:. 4. 5. 6. No cDNA. - Ac. - Ac. - Ac. - Ac.

102 views • 4 slides

Supplemental Figure 1

Supplemental Figure 1. c. . MGC-803. 4. 4. 3. 3. miR-185 levels (fold). 40. TUNEL positive cells (%). 2. 2. . 1. 1. 20. 0. 0. . 60. 60. 0. –. CDDP(30 m M). +. +. +. TUNEL positive cells (%). 40. 40. . –. –. –. miR-185 AntagomiR. +. –. –. –.

74 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. a. Relative expression. b. Relative expression. c. Relative expression.

101 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. B. A. g H2AX. TRF1. Merge. 100. Untreated. 80. 60. % of TIFs positive cells. 40. RHPS4. 20. 0. _. RHPS4. siTRF2. siPOT1. CPT. IR. siTRF2. siPOT1. CPT. IR.

116 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. Supplemental Figure 1 . Southern of AtplaIVC-1

79 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. True leaf from 2 nd to 7 th nodes. (a). M. 1 st (IN) IN. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. PC. ALSV-RNA2. 7. PsEF1- a. 6. 1. 2. 3. 5. True leaf from 2 nd to 7 th nodes. ALSV inoculation. 4. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. 3. Mock. 2.

96 views • 3 slides

Supplemental Figure 1

Vimentin. FLAG/Luc/#1. FLAG/Keap1/#1. FLAG/Luc/#1 FLAG/Keap1/#1. B. Supplemental Figure 1. A. Supplemental Figure 2. GSH. 25,000,000. 20,000,000. Relative Intensity. 15,000,000. 10,000,000. 5,000,000. 0. Control. Nrf2 shRNA/#2. Levels of ROS. A. B. Control.

213 views • 10 slides

Supplemental figure 1

Supplemental figure 1. A. B. LFN. naked DNA. C. D. 【 Ad genome 】. 【 pDNA 】. Amount of DNA. Amount of DNA. ( ×10 9 copies). ( ×10 10 copies). 1.1. 2.1. 4.3. 0.85. 1.7. 3.4. 6.8. E. F. 【 Ad genome 】. 【 pDNA 】. 25. 60. y = 8.0×10 -10 x + 0.030 R 2 = 0.989.

79 views • 2 slides

Supplemental Figure 1

Supplemental Figure 1. A. Obj 1. Obj 2. Obj 3. Obj 4. Obj 5. B. Bio16. C. mCT. Transconvolution and the Virtual Positron Emission Tomograph (vPET) – A New Method for Cross Calibration in Quantitative PET/CT Imaging

138 views • 1 slides

Supplemental Figure 1

Serum concentration of cTnT. Activity of MMP-2/9. Before CPB. AfterCPB. Supplemental Figure 1.

75 views • 1 slides

Supplemental Figure 1

2500. 2000. 1500. 1000. 500. Supplemental Figure 1. CS-0777 product [ ng/mL ･ mg protein ]. 0. #1. #2. #3. #4. #5. Human specimen number. Supplemental figure 1. Examination of individual specificity of CS-0777-P phosphatase activity

226 views • 7 slides

Supplemental Figure 1.

Supplemental Figure 1. Immunohistochemistry for Hic-5 in human small intestine. In the epithelial cells, Hic-5 appears to be localized primarily in the apical portion of the epithelium.

75 views • 1 slides

Supplemental Figure 1

B. Axonal Blebbing. t = 0 min. t = 0 min. t = 5 min. t = 5 min. t = 10 min. t = 10 min. t = 15 min. t = 15 min. t = 20 min. t = 20 min. A. Growth Cone Ruffling. D. Average Positive Particle Velocity Histogram. C. WGA Kymograph (4 hr incubation). 0 min. Time. *. 20 min.

195 views • 2 slides

Supplemental Figure 1

Supplemental Figure 1. A. B. panobinostat. Supplemental Figure 2. Control. 20. 50 nM BC2059, 24 hr. A. OCI-AML3. B. Supplemental Figure 2. Control. 20. 50. 100 nM BC2059, 48 hr. C. OCI-AML3. TO-PRO-3 iodide. Annexin V-FITC. D. Control. 50.

130 views • 12 slides

More Related